Researcher
Koen Van de Vijver
- Disciplines:Diagnostics, Medicinal products, Laboratory medicine
Affiliations
- Department of Diagnostic Sciences (Department)
Member
From1 Oct 2018 → Today - Department of Medical and Forensic Pathology (Department)
Member
From1 Aug 2018 → 30 Sep 2018
Projects
1 - 1 of 1
- Heading towards an in vivo predictive test for personalized ovarian cancer treatment: application of novel therapies in zebrafish patient derived xenograftsFrom1 Nov 2019 → TodayFunding: FWO Strategic Basic Research Grant
Publications
1 - 10 of 137
- Histologic tumor type as a determinant of survival in hormone receptor-positive, HER2-negative, pT1-3 invasive ductal and lobular breast cancer(2023)
Authors: Menekse GOKER, Hannelore Denys, An Hendrix, Olivier De Wever, Koen Van de Vijver, Geert Braems
- Ovotesticular difference of sex development : genetic background, histological features and clinical management(2023)
Authors: Hannes Syryn, Koen Van de Vijver, Martine Cools
Pages: 180 - 189 - Pembrolizumab, radiotherapy, and an immunomodulatory five-drug cocktail in pretreated patients with persistent, recurrent, or metastatic cervical or endometrial carcinoma : results of the phase II PRIMMO study(2023)
Authors: Emiel De Jaeghere, Sandra Tuyaerts, An M. T. Van Nuffel, Ann Belmans, Kris Bogaerts, Regina Baiden-Amissah, Peter Vuylsteke, Stéphanie Henry, Xuan Bich Trinh, Peter A. van Dam, et al.
Pages: 475 - 491 - Characteristics of long-term survival in advanced stage ovarian cancer : a nationwide cohort in the Netherlands(2022)
Authors: Lilian van Wagensveld, Gabe Steven Sonke, Koen Van de Vijver, Hugo Mark Horlings, Rutgerus Franciscus Petrus Maria Kruitwagen, Maaike Anne van der Aa
Pages: 1 - 9 - Homologous recombination repair deficiency (HRD) testing in newly diagnosed advanced-stage epithelial ovarian cancer : a Belgian expert opinion(2022)
Authors: I Vergote, Hannelore Denys, S. Altintas, J. Kerger, J-F Baurain, V Bours, S. Henry, Koen Van de Vijver, D. Lambrechts, C. Gennigens
Pages: 111 - 120 - Effect of HIPEC according to HRD/BRCAwt genomic profile in stage III ovarian cancer : results from the phase III OVHIPEC trial(2022)
Authors: Simone N. Koole, Philip C. Schouten, Jan Hauke, Roel J. C. Kluin, Petra Nederlof, Lisa K. Richters, Gabriele Krebsbach, Karolina Sikorska, Maartje Alkemade, Mark Opdam, et al.
Pages: 1394 - 1404 - 2022-RA-638-ESGO Pembrolizumab with multimodal immunomodulation in chemotherapy-pretreated cervical, endometrial, and uterine cancer : the PRIMMO phase II trial(2022)Volume: 32
Authors: Emiel De Jaeghere, Sandra Tuyaerts, Ann M.T. van Nuffel, Ann Belmans, Kris Bogaerts, Regina Baiden-Amissah, Peter Vuylsteke, Stéphanie Henry, Xuan Bich Trinh, Peter A. van Dam, et al.
Pages: A187 - A188 - Update to the Belgian follow-up guidelines for abnormal cervical screening results(2022)
Authors: Claire Bourgain, Birgit Weynand, Koen Van de Vijver, Shahebali Shaira
Pages: 60 - 69 - Extrauterine mesonephric-like neoplasms : expanding the morphologic spectrum(2022)
Authors: Ellen Deolet, Iteeka Arora, Jo Van Dorpe, Joni Van der Meulen, Sudha Desai, Nadine Van Roy, Baljeet Kaur, Koen Van de Vijver, W Glenn McCluggage
Pages: 124 - 133 - Guidelines for the detection of NTRK fusions : a report from the Belgian Molecular Pathology Working Group(2021)
Authors: Patrick Pauwels, Glenn Broeckx, Franceska Dedeurwaerdere, Christine Galant, Aline Hébrant, Isabelle Vanden Bempt, Koen Van de Vijver, Jacques Van Huysse, Birgit Weynand, Nicky D'Haene
Pages: 112 - 116